Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.
about
Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets.Pioglitazone Protected against Cardiac Hypertrophy via Inhibiting AKT/GSK3β and MAPK Signaling Pathways.Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways.AdipoRon, an adiponectin receptor agonist, attenuates PDGF-induced VSMC proliferation through inhibition of mTOR signaling independent of AMPK: Implications toward suppression of neointimal hyperplasia.Sulforaphane inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation by targeting mTOR/p70S6kinase signaling independent of Nrf2 activation.Cellular and Molecular Mechanisms of Diabetic Atherosclerosis: Herbal Medicines as a Potential Therapeutic Approach.Folic acid inhibits dedifferentiation of PDGF-BB-induced vascular smooth muscle cells by suppressing mTOR/P70S6K signalingEffects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice.High fructose-mediated attenuation of insulin receptor signaling does not affect PDGF-induced proliferative signaling in vascular smooth muscle cells.Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks.Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study.PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review).Rosmarinic acid attenuates cardiac fibrosis following long-term pressure overload via AMPKα/Smad3 signaling.Pioglitazone Attenuates Injury-Induced Neointima Formation in Mouse Femoral Artery Partially through the Activation of AMP-Activated Protein Kinase.Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signaling
P2860
Q33808884-EE87AF0E-13BC-42F1-ADA2-29491F9E6107Q36783984-2593265C-80A5-4202-B3E7-91E884B7E874Q37310692-0CF7892E-AC2B-4880-B8EB-FE9D5CBBF97BQ38714857-FDDC4D96-D6EF-4522-9765-7EEB42ECE3A2Q38716001-1C926627-E243-4FE7-AC51-3F4A4C86D00AQ41528907-204EA869-C875-4957-9329-1896B911153FQ42068247-4BE80265-0E4C-4049-800B-DBCAC954CAA9Q42366433-82F00BA6-45DC-47DF-BB23-8627308B1F6CQ44406447-7A8A10EE-1BC6-4ECB-B434-BA14B991418CQ47096436-C8EAE534-6A6E-4DFA-A203-5E9865BCF09FQ47746064-7A19767A-9933-4D76-9FC3-C3CEF94D4DD6Q49568112-4A895416-A229-4EE3-A23E-5F307BB1777FQ49724539-80312075-6F9C-46C7-B325-D69687314115Q51014952-FD2A356C-7376-4211-A1A3-861D0CD05628Q58761757-62C7EF23-F756-4D6D-88B7-6F2991C59303
P2860
Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pioglitazone, a PPARγ agonist, ...... mTOR/p70S6K and ERK signaling.
@ast
Pioglitazone, a PPARγ agonist, ...... mTOR/p70S6K and ERK signaling.
@en
type
label
Pioglitazone, a PPARγ agonist, ...... mTOR/p70S6K and ERK signaling.
@ast
Pioglitazone, a PPARγ agonist, ...... mTOR/p70S6K and ERK signaling.
@en
prefLabel
Pioglitazone, a PPARγ agonist, ...... mTOR/p70S6K and ERK signaling.
@ast
Pioglitazone, a PPARγ agonist, ...... mTOR/p70S6K and ERK signaling.
@en
P2860
P1476
Pioglitazone, a PPARγ agonist, ...... mTOR/p70S6K and ERK signaling
@en
P2093
Lakshman Segar
P2860
P356
10.1016/J.BCP.2015.11.026
P407
P50
P577
2015-11-28T00:00:00Z